These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 19884854

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
    Pluquet E, Cadranel J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D.
    J Thorac Oncol; 2010 Apr; 5(4):491-6. PubMed ID: 20195171
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N.
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [Abstract] [Full Text] [Related]

  • 11. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK.
    Int J Radiat Oncol Biol Phys; 2015 Jun 01; 92(2):317-24. PubMed ID: 25968826
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).
    Tseng YH, Hung HY, Sung YC, Tseng YC, Lee YC, Whang-Peng J, Chen YM.
    J Chemother; 2016 Jun 01; 28(1):50-8. PubMed ID: 25976428
    [Abstract] [Full Text] [Related]

  • 13. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
    Massabeau C, Filleron T, Wakil G, Rouquette I, Bachaud JM, Leguellec S, Delisle MB, Toulas C, Mazieres J, Cohen-Jonathan Moyal E.
    Clin Lung Cancer; 2012 Jan 01; 13(1):59-67. PubMed ID: 21856239
    [Abstract] [Full Text] [Related]

  • 14. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK, Wai E, Alexander C, Tyldesley S, Murray N.
    J Thorac Oncol; 2012 Jul 01; 7(7):1155-63. PubMed ID: 22617240
    [Abstract] [Full Text] [Related]

  • 15. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M, Okayama Lung Cancer Study Group.
    J Thorac Oncol; 2010 Jan 01; 5(1):99-104. PubMed ID: 19898258
    [Abstract] [Full Text] [Related]

  • 16. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
    Chang CC, Chi KH, Kao SJ, Hsu PS, Tsang YW, Chang HJ, Yeh YW, Hsieh YS, Jiang JS.
    Lung Cancer; 2011 Aug 01; 73(2):189-94. PubMed ID: 21247653
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
    Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T.
    J Thorac Oncol; 2009 Feb 01; 4(2):214-9. PubMed ID: 19179899
    [Abstract] [Full Text] [Related]

  • 18. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.
    Davidoff AJ, Gardner JF, Seal B, Edelman MJ.
    J Thorac Oncol; 2011 May 01; 6(5):934-41. PubMed ID: 21372743
    [Abstract] [Full Text] [Related]

  • 19. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF.
    Lung Cancer; 2015 Sep 01; 89(3):255-61. PubMed ID: 26117231
    [Abstract] [Full Text] [Related]

  • 20. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
    Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K.
    J Thorac Oncol; 2013 Jun 01; 8(6):753-8. PubMed ID: 23575412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.